Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. reports developments tied to its commercial oncology business and selinexor-based drug development. The company markets XPOVIO (selinexor) and reports U.S. product revenue, license and other revenue, liquidity, and operating updates alongside its periodic financial results.
Recurring KPTI news also covers late-stage clinical programs evaluating selinexor in cancer indications, including the Phase 3 SENTRY trial in myelofibrosis and the Phase 3 XPORT-EC-042 trial in endometrial cancer. Company updates include clinical data presentations, regulatory-development disclosures, equity inducement grants under Nasdaq rules, financing activity, and other corporate and capital-structure matters.
Karyopharm (Nasdaq: KPTI) reported first quarter 2026 total revenue of $35.1 million, including $29.2 million U.S. XPOVIO net product revenue, and reaffirmed 2026 revenue guidance of $130–$150 million. The company completed enrollment in its Phase 3 endometrial cancer trial and reported pivotal Phase 3 SENTRY myelofibrosis results.
Karyopharm (Nasdaq: KPTI) announced that senior management will participate in two May 2026 investor conferences via fireside chats: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the RBC 2026 Global Healthcare Conference, both on May 19, 2026.
Live webcasts and replays will be available in the Events & Presentations section of Karyopharm's investor relations website.
Karyopharm (Nasdaq: KPTI) will report first quarter 2026 financial results on Thursday, May 14, 2026. Management will host a conference call and live audio webcast at 8:00 a.m. ET to discuss results and company updates. Slides and an archived webcast will be available on the investor website approximately two hours after the event.
Karyopharm (Nasdaq: KPTI) said its late-breaking abstract from the Phase 3 SENTRY trial in myelofibrosis was accepted for an oral presentation at the ASCO 2026 Annual Meeting in Chicago.
The presentation covers 60 mg selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis (Abstract LBA6500), scheduled for June 2, 2026 at 9:45 a.m.–12:45 p.m. CT. According to the company, the presentation copy will be posted after the event under "Publications and Presentations" in Investor Relations.
Karyopharm (Nasdaq: KPTI) entered a private placement with RA Capital expected to raise approximately $30 million in gross proceeds, with an additional $44 million/b) if accompanying warrants are exercised in full. The financing includes 1,030,354 common shares, 3,391,164 pre-funded warrants, and warrants for 4,421,518 shares.The offering was priced at-the-market under Nasdaq rules and is expected to close on or about March 26, 2026. Net proceeds plus existing liquidity are expected to fund operations into late Q3 2026. Proceeds are for general corporate purposes and planned clinical trial activities.
Karyopharm (Nasdaq: KPTI) reported topline Phase 3 SENTRY results in frontline myelofibrosis (n=353). The trial met its first co-primary endpoint: SVR35 50% vs 28% at Week 24 (one-sided p<0.0001) for selinexor plus ruxolitinib. The Abs-TSS symptom endpoint was not met. A promising overall survival signal (HR 0.43) was observed; safety showed higher grade 3+ TEAEs with the combination.
Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,450 restricted stock units (RSUs) to two newly hired employees, effective Feb 28, 2026, under its 2022 Inducement Stock Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Each RSU vests over three years with 33 1/3% vesting on each consecutive anniversary and is contingent on continued service through each vesting date.
Karyopharm (Nasdaq: KPTI) reported full‑year 2025 total revenue of $146.1M and U.S. XPOVIO net product revenue of $114.9M. The company reiterated 2026 guidance of $130M–$150M total revenue and $115M–$130M U.S. XPOVIO revenue.
Key clinical catalysts include Phase 3 SENTRY top‑line data expected in March 2026 and Phase 3 XPORT‑EC‑042 data expected in mid‑2026. Cash and financing items drove a $196.0M net loss for 2025 and a cash balance of $64.1M at year‑end.
Karyopharm (Nasdaq: KPTI) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will host a conference call and live audio webcast at 8:00 a.m. ET to discuss results and company updates.
Dial-in numbers are provided for domestic and international callers, and accompanying slides plus an archived webcast will be available on the company’s Investor "Events & Presentations" webpage about two hours after the call.
Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,799 restricted stock units (RSUs) to four newly hired employees, effective January 31, 2026, under its 2022 Inducement Stock Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4).
Each RSU vests over three years with 33 1/3% vesting on each anniversary, conditioned on continued service through each vesting date.